Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9P1Z2
UPID:
CACO1_HUMAN
Alternative names:
Calphoglin; Coiled-coil coactivator protein; Sarcoma antigen NY-SAR-3
Alternative UPACC:
Q9P1Z2; B3KVA8; Q6FI59; Q71RC3; Q86WF8; Q96JU3; Q9H090
Background:
Calcium-binding and coiled-coil domain-containing protein 1, also known as Calphoglin, plays a pivotal role as a coactivator for various transcription factors, including aryl hydrocarbon and nuclear receptors. It is instrumental in the transcriptional activation of genes within the Wnt/CTNNB1 pathway and acts as a secondary coactivator in LEF1-mediated transcription. Its involvement extends to enhancing inorganic pyrophosphatase activity, linking cellular metabolism with core functions such as protein synthesis and calcium signaling.
Therapeutic significance:
Understanding the role of Calcium-binding and coiled-coil domain-containing protein 1 could open doors to potential therapeutic strategies.